Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Bozzino

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cancer Treatment Reports|March 1, 1981
Avoidance of renal toxicity by 24-hour infusion of cisplatinJ M Bozzino, V Prasad, O M Koriech
Cancer Chemotherapy and Pharmacology|January 1, 1986
Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancerB M Cantwell, A L Harris, J M Bozzino
British Medical Journal|July 9, 1977
Commitment to oncologyR G Evans, I C Paterson, J M Bozzino
European Journal of Cancer & Clinical Oncology|February 1, 1988
The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancerB M Cantwell, J M Bozzino, P Corris, et al.
Plastic and Reconstructive Surgery|April 4, 2006
Occam's razor revisited: potential hazards of multiple pathologyS M Azad, P M Geary, P Sugden, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 1, 1990
Treatment of carcinoma of the breast with high dose oral medroxyprogesterone acetate: does increased bioavailability improve the therapeutic ratio?J T Roberts, T Bates, J M Bozzino, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cancer Treatment Reports|March 1, 1981
Avoidance of renal toxicity by 24-hour infusion of cisplatinJ M Bozzino, V Prasad, O M Koriech
Cancer Chemotherapy and Pharmacology|January 1, 1986
Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancerB M Cantwell, A L Harris, J M Bozzino
British Medical Journal|July 9, 1977
Commitment to oncologyR G Evans, I C Paterson, J M Bozzino
European Journal of Cancer & Clinical Oncology|February 1, 1988
The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancerB M Cantwell, J M Bozzino, P Corris, et al.
Plastic and Reconstructive Surgery|April 4, 2006
Occam's razor revisited: potential hazards of multiple pathologyS M Azad, P M Geary, P Sugden, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 1, 1990
Treatment of carcinoma of the breast with high dose oral medroxyprogesterone acetate: does increased bioavailability improve the therapeutic ratio?J T Roberts, T Bates, J M Bozzino, et al.
Pageof 1